RxDoctor Payments DataLook up a doctor →

Nasser Nasseriasl, MD

Rheumatology · Catonsville, MDNPI 1437119047

Payments from drug & device makers

$135,741in general payments, 2019–2025

Across 402 payments — averaging $337.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$127K
  • GSK$3K
  • Bristol Myers Squibb$1K
  • AbbVie$812
  • Pfizer$560
  • Johnson & Johnson$557
  • plus $2K from 26 others

What the payments were for

  • Consulting fees$3830%
  • Speaking & faculty fees$127,97694%
  • Travel & lodging$3200%
  • Food & beverage$7,0275%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$135,741 in reported general payments places this provider in the 85th percentile of 173 rheumatology providers in Maryland.

See all rheumatology providers in Maryland

Medicare billing

Part B allowed, 2024
$3,908,734
Medicare patients
876
Services billed
218,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrenciaAbatacept/Maltose66$353,717
Simponi AriaGolimumab17$172,553
Humira(Cf) PenAdalimumab16$167,112
SimponiGolimumab16$100,539
OtezlaApremilast17$84,481
Hydroxychloroquine Sulfate300$19,500
Diclofenac Sodium31$17,448
RasuvoMethotrexate/Pf11$10,314
MethotrexateMethotrexate Sodium239$9,279
Leflunomide121$9,231
Febuxostat34$5,238
Prednisone385$2,745
Methylprednisolone65$1,439
Sulfasalazine29$1,217
Allopurinol71$819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Orencia$447$353,71766 claims
Johnson & JohnsonSimponi Aria, Simponi$557$273,09133 claims
AmgenOtezla$126,879$84,48117 claims
Medexus Pharma, Inc.Rasuvo$12$10,31411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 173 rheumatology providers in Maryland.

Other rheumatology in Catonsville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →